BioWorld

March 13, 2003

View Archived Issues

One Chain Of Virulent Ricin Toxin Forms Cancer-Fighting Therapies In Mice, Humans, But With Kicker

Read More

FDA's ODAC Meeting Examines Accelerated Approval Process

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

OSI Buying Cancer Rights To Serono's Novantrone For $55M

Oncology company OSI Pharmaceuticals Inc. is fronting $55 million to Serono SA for U.S. marketing rights to the cancer indications of a long-approved but oft-shuffled drug. (BioWorld Today) Read More

European Companies Move Into Survival Mode, Wait For Upturn

Read More